504A
Innovacell Inc.
イノバセル
- Industry
- Pharmaceutical
- Market
- Growth
- Accounting standards
- Japanese GAAP
- Consolidation basis
- Consolidated
Key metrics
Revenue(-)
Dec 2025
-
Operating profit(thousand JPY)
Dec 2025
-2,231,686
Operating profit margin(-)
Dec 2025
-
Profit before tax(thousand JPY)
Dec 2025
-2,853,829
Profit(thousand JPY)
Dec 2025
-2,855,124
Total assets(thousand JPY)
Dec 2025
5,092,561
Cash and cash equivalents(thousand JPY)
Dec 2025
4,101,476
Cash flows from operating activities(thousand JPY)
Dec 2025
-1,995,296
Cash flows from investing activities(thousand JPY)
Dec 2025
-53,732
Cash flows from financing activities(thousand JPY)
Dec 2025
4,089,625
Return on equity(-)
Dec 2025
-
Equity ratio(-)
Dec 2025
-
Earnings per share(JPY per share)
Dec 2025
-89
Net assets per share(JPY per share)
Dec 2025
-78.95
Dividend per share(-)
Dec 2025
-
Payout ratio(-)
Dec 2025
-
Disclaimer
The financial information and metrics on this page are based on publicly available filings and other public sources. We do not guarantee their accuracy, completeness, or timeliness.
The information on this page is provided for reference purposes only and does not constitute a recommendation to buy or sell any security. Investment decisions should be made at your own responsibility.